- Home
- CZR vs MIRM Comparison
CZR vs MIRM Comparison
Compare CZR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CZR | MIRM |
|---|---|---|
| Founded | 1937 | 2018 |
| Country | United States | United States |
| Employees | 15500 | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 7.2B |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CZR | MIRM |
|---|---|---|
| Price | $30.18 | $97.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $31.92 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 3.3M | 673.0K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,473,504,000.00 | $19,138,000.00 |
| Revenue This Year | $3.56 | $26.22 |
| Revenue Next Year | $2.48 | $22.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 65.03 | N/A |
| 52 Week Low | $17.86 | $63.23 |
| 52 Week High | $30.88 | $130.00 |
Technical Indicators
Market Signals| Indicator | CZR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 57.94 | 37.02 |
| Support Level | $29.50 | $95.68 |
| Resistance Level | $30.86 | $98.03 |
| Average True Range (ATR) | 0.23 | 4.86 |
| MACD | 0.01 | -2.01 |
| Stochastic Oscillator | 92.40 | 31.25 |
Price Performance
Historical ComparisonAbout CZR Caesars Entertainment Inc.
Caesars Entertainment's stand-alone portfolio includes about 50 domestic gaming properties across the Las Vegas (48% of 2025 EBITDAR) and regional (49%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2025. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform. The portfolio is set to expand to more than 60 casinos with the proposed acquisition of Caesars by Fertitta Entertainment and its Golden Nugget resorts.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.